RxDoctor Payments Data

Pamela Dugano-Daphnis, MD

Internal Medicine · Webster, TXNPI 1982695037

Payments from drug & device makers

$20,066in general payments, 2019–2025

Across 1,132 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novo Nordisk$2K
  • GSK$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Merck$1K
  • plus $9K from 46 others

What the payments were for

  • Consulting fees$600%
  • Food & beverage$19,20798%
  • Education$2361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,066 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,425
Medicare patients
105
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$161,709
FarxigaDapagliflozin Propanediol38$56,988
Tresiba Flextouch U-200Insulin Degludec40$49,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$37,279
JanuviaSitagliptin Phosphate27$35,977
MounjaroTirzepatide27$34,948
Xigduo XrDapaglifloz Propaned/Metformin37$34,485
RybelsusSemaglutide16$24,527
TrulicityDulaglutide13$18,579
JardianceEmpagliflozin19$15,087
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$5,545
PristiqDesvenlafaxine Succinate19$5,238
Rosuvastatin Calcium314$4,911
Atorvastatin Calcium473$3,879
Fenofibrate94$3,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,708$186,236116 claims
AstraZenecaFarxiga$3,964$56,98838 claims
Lilly USA, LLCMounjaro, Trulicity$1,205$53,52740 claims
GSKTrelegy Ellipta$1,677$37,27939 claims
MerckJanuvia$1,130$35,97727 claims
Boehringer IngelheimJardiance$308$15,08719 claims
Indivior Inc.Suboxone$185$5,54512 claims
PfizerPristiq$586$5,23819 claims
AbbVieSynthroid$1,653$3,79247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →